Overall, beyond their established metabolic effects, GLP-1RAs may orchestrate a network of neurophysiological and biochemical processes that intersect with mood and behavior regulation
Still, this combination should be managed by both your dermatologist and endocrinologist for safety, particularly if you are also on topical corticosteroids or antibiotics for skin infection
Triple Agonist vs Dual Agonist Comparison Contents Key Takeaways Two Compounds, One Manufacturer, Different Receptor Counts Weight Loss: The Numbers Side by Side Mechanism Breakdown: What the Third Receptor Adds Safety: Where the Tradeoffs Appear Evidence Quality: Phase 2 vs Phase 3 Where Each Compound Might Win The Bottom Line Explore Research Peptides Retatrutide 12mg 24.2% body weight lost (Phase 2, 48 wk) vs Tirzepatide 15mg 22.5% body weight lost (Phase 3, 72 wk) 3 vs 2 receptor targets (retatrutide vs tirzepatide) 63% vs 57% reached 20%+ weight loss (highest dose arms) Eli Lilly same manufacturer for both compounds Sources: Retatrutide Phase 2 (NEJM, 2023), SURMOUNT-1 (NEJM, 2022)
Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain
Medications, existing liver or kidney disease, and concurrent supplement use can alter glutathione metabolism and efficacy
